Business / Finance

RSS

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Vygon, a French family-run business that develops, produces and markets medical devices, including catheters and implantable ports for administering chemotherapy treatments, today announce their partnership to develop a new generation of innovative medical devices; mainly for use in chemotherapy. The partnership aims to introduce them to European, the US and Asian markets.

16 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Columbia Laboratories amends license, supply agreement with Merck Serono for CRINONE

Columbia Laboratories, Inc. has amended its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE (progesterone gel) through May 2020, representing an extension of five years beyond the current term, which was due to expire in May 2015.

10 Apr 2013

Business Network Services from Anglia Ruskin: an interview with Prof Young

The Anglia Ruskin Medtech Campus Business Network Services have been developed in partnership with Chelmsford City Council, Harlow District Council and Southend-on-Sea Borough Council as part of plans to form the largest MedTech cluster in the UK over three development sites in Essex.

8 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

Acadia Healthcare signs agreement to purchase two acute inpatient psychiatric facilities

Acadia Healthcare Company, Inc. today announced that it has signed a definitive purchase agreement with Ten Broeck Tampa, Inc. and Capestrano Investment Company, Inc. to purchase two acute inpatient psychiatric facilities.

5 Apr 2013

Diaverum acquires four clinics in Hamburg, Germany

Diaverum, one of the world's leading, product-independent renal care providers, has announced the major acquisition of the four clinics that make up the Alte Teichweg centre in Hamburg, Germany.

4 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Biogen acquires TYSABRI stake from Elan

Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.

3 Apr 2013

Microbiology testing services now offered by Ceram

Ceram, the international materials testing and development company, has announced that it is now offering microbiology testing services for the healthcare industries, thanks to a partnership with a leading UK microbiological testing lab.

2 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

Chromatrap chromatin immunoprecipitation (ChIP) assay range added to Porvair Sciences’ portfolio of products for epigenetics

Porvair Sciences has announced the addition of the novel Chromatrap chromatin immunoprecipitation (ChIP) assay range to its portfolio of products for epigenetics.

From Chromatrap® - Porvair Sciences Ltd 28 Mar 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

Clinigen announces acquisition of Cardioxane from Novartis

Clinigen Group plc today announced the acquisition of Cardioxane (dexrazoxane) from Novartis for US$33 million in cash, payable in two tranches.

From Clinigen Group 26 Mar 2013

European mobile health market to reach €2.45 billion in 2016

The European mobile health market forecasts strikingly high growth rates in coming years, despite the global financial crisis. Frost & Sullivan expects the market to grow from €393 million in 2011 to €2.45 billion in 2016 therefore, creating vast opportunities for industry players.

19 Mar 2013

AGA, CDC partner to promote free colonoscopies for uninsured patients

Colorectal cancer (CRC) is the second leading cause of cancer deaths among men and women nationwide. During National Colorectal Cancer Awareness Month, the Centers for Disease Control and Prevention (CDC) and the American Gastroenterological Association (AGA) are joining forces for the second year to promote free colonoscopies for uninsured patients.

19 Mar 2013

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

From Luminex 15 Mar 2013

Business Network Services to be launched by Anglia Ruskin MedTech Campus

Companies from across the medical technology sector will be offered improved access to the NHS and global markets when the Anglia Ruskin MedTech Campus launches its Business Network Services on Wednesday, 13 March.

7 Mar 2013

IMRIS fourth quarter total revenues increase 37% to $20.1 million

IMRIS Inc. today reported its results for the fourth quarter and full year of 2012. All figures are reported in US dollars.

5 Mar 2013

Business / Finance

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

COPD phase III study by Almirall and Forest Laboratories announces positive results

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Columbia Laboratories amends license, supply agreement with Merck Serono for CRINONE

Business Network Services from Anglia Ruskin: an interview with Prof Young

GenSight Biologics announces closing of €32 million Series A financing

Acadia Healthcare signs agreement to purchase two acute inpatient psychiatric facilities

Diaverum acquires four clinics in Hamburg, Germany

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Biogen acquires TYSABRI stake from Elan

Microbiology testing services now offered by Ceram

Revance Therapeutics raises $33M in Series E financing

Chromatrap chromatin immunoprecipitation (ChIP) assay range added to Porvair Sciences’ portfolio of products for epigenetics

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Clinigen announces acquisition of Cardioxane from Novartis

European mobile health market to reach €2.45 billion in 2016

AGA, CDC partner to promote free colonoscopies for uninsured patients

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

Business Network Services to be launched by Anglia Ruskin MedTech Campus

IMRIS fourth quarter total revenues increase 37% to $20.1 million

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News